Looking at the filing, I can confirm this is a Form 10-K for Reviva Pharmaceuticals Holdings, Inc., with the common stock listed on The Nasdaq Capital Market under the ticker RVPH. The filing covers the fiscal year ended December 31, 2025. The substantive disclosure content includes share count (12,810,377 as of March 27, 2026), aggregate market value of non-affiliate equity (~$21.4 million as of June 30, 2025), par value ($0.0001 per share), company address (Cupertino, CA), and filer classifications (non-accelerated filer, smaller reporting company). This exceeds 150 words of substantive content when combined with the cover page disclosures, so I will proceed.

Reviva Pharmaceuticals Holdings, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2025, with the Securities and Exchange Commission on November 9, 2026, disclosing share count, market capitalization, and company classification details.

Key Highlights

  • Share count: As of March 27, 2026, the company had 12,810,377 shares of common stock outstanding, each with a par value of $0.0001 per share.
  • Non-affiliate market value: The aggregate market value of voting and non-voting common equity held by non-affiliates was approximately $21.4 million, based on the closing price on June 30, 2025, as reported by the Nasdaq Capital Market.
  • Filer classification: The company is classified as a non-accelerated filer and a smaller reporting company, according to the filing.
  • Exchange listing: The common stock trades on the Nasdaq Capital Market under the symbol RVPH (NASDAQ:RVPH), as stated on the cover page.
  • Shell company status: The registrant indicated it is not a shell company as defined in Rule 12b-2 of the Exchange Act.
  • No documents incorporated by reference: The filing states "None" under documents incorporated by reference.

Reviva Pharmaceuticals Annual Disclosure: Fiscal Year 2025 Cover Details

Reviva Pharmaceuticals Holdings, Inc., a Delaware-incorporated pharmaceutical company headquartered at 10080 N Wolfe Road, Suite SW3-200, Cupertino, CA 95014, submitted its Form 10-K annual report covering the fiscal year ended December 31, 2025. The filing carries Commission File Number 001-38634 and identifies the company's I.R.S. Employer Identification Number as 85-4306526, according to the cover page disclosures.

The company disclosed that as of March 27, 2026, there were 12,810,377 shares of common stock outstanding at a par value of $0.0001 per share. The aggregate market value of common equity held by non-affiliates was approximately $21.4 million, computed using the closing price on June 30, 2025, as reported by the Nasdaq Capital Market. The filing notes that this calculation "does not reflect a determination that certain persons are affiliates of the registrant for any other purpose," according to the company's own language in the filing.

Reviva Pharmaceuticals is classified in the filing as a non-accelerated filer and a smaller reporting company, and it confirmed it is not an emerging growth company. The registrant also confirmed it is not a shell company. The filing contains forward-looking statements made pursuant to safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and the company has noted that such statements are not guarantees of performance and "involve known and unknown risks," as stated in the cautionary note within the filing. The report's table of contents references business operations, risk factors, cybersecurity disclosures, executive compensation, and financial statements among its covered topics.

What Was Disclosed

Reviva Pharmaceuticals Holdings, Inc. filed its fiscal year 2025 annual report, disclosing 12,810,377 shares outstanding as of March 27, 2026, a non-affiliate equity market value of approximately $21.4 million as of June 30, 2025, and its status as a non-accelerated, smaller reporting company listed on NASDAQ:RVPH.